SATIO
DEAD

Serial Number

97512123

Owner

Satio, Inc.

Attorney

Joshua S. Jarvis, Esq.

Filing Date

Jul 20, 2022

Add to watchlist:

No watchlists yet
View on USPTO

SATIO Trademark

Serial Number: 97512123

SATIO is a trademark filed by Satio, Inc. on July 20, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently no longer active.

Owner Contact Info

Satio, Inc. (10 trademarks)

27 Drydock Ave., 3rd Floor
Boston, MA 02210

Entity Type: 03

Trademark Details

Filing Date

July 20, 2022

Registration Date

Not Registered

Published for Opposition

September 5, 2023

Goods & Services

Medical diagnostic apparatus for testing DNA and RNA samples; medical diagnostic apparatus for testing for infectious diseases and non-infectious diseases, namely, hepatic diseases, immune system diseases, renal diseases, metabolic diseases, endocrine diseases, thyroid diseases, diabetes, pancreatic diseases, cystic fibrosis, phenylketonuria, blood diseases, sickle cell disease, sickle cell anemia, galactosemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency; genetic testing apparatus for medical purposes; dermal patches for delivery of pharmaceuticals and vaccines, sold empty; medical devices for obtaining body fluid samples; medical devices for testing body fluid samples; dermal patches for testing DNA and RNA samples; dermal patches for testing for infectious diseases and non-infectious diseases, namely, hepatic diseases, , immune system diseases, renal diseases, metabolic diseases, endocrine diseases, thyroid diseases, diabetes, pancreatic diseases, cystic fibrosis, phenylketonuria, blood diseases, sickle cell disease, sickle cell anemia, galactosemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency; dermal patches for testing for genetic testing; dermal patches for obtaining body fluid samples; dermal patches for testing body fluid samples

Vaccines, namely, dermal patches featuring vaccines; pharmaceutical preparations for the prevention and treatment of infectious diseases and non-infectious diseases, namely, dermal patches featuring pharmaceutical preparations for the prevention and treatment of hepatic diseases, immune system diseases, renal diseases, metabolic diseases, endocrine diseases, thyroid diseases, diabetes, pancreatic diseases, cystic fibrosis, phenylketonuria, blood diseases, sickle cell disease, sickle cell anemia, galactosemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency; medical diagnostic reagents and assays for testing of body fluids, namely, dermal patches featuring medical diagnostics or assays for testing of body fluids; reagents for use in medical genetic testing, namely, dermal patches featuring reagents for use in medical genetic testing

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 1, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 1, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 4, 2025 EXRA
SOU EXTENSION 3 GRANTED
Apr 3, 2025 EX3G
SOU EXTENSION 3 FILED
Apr 3, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 3, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 18, 2024 EXRA
SOU EXTENSION 2 GRANTED
Sep 18, 2024 EX2G
SOU EXTENSION 2 FILED
Sep 18, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Sep 18, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 27, 2024 EXRA
SOU EXTENSION 1 GRANTED
Apr 26, 2024 EX1G
SOU EXTENSION 1 FILED
Apr 26, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 26, 2024 EEXT
CORRECTED NOA E-MAILED
Nov 30, 2023 NOAC
NOTICE OF ALLOWANCE CORRECTION ENTERED
Nov 29, 2023 ICNA
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 9, 2023 AITU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 31, 2023 NOAM
TEAS POST PUBLICATION AMENDMENT RECEIVED
Oct 24, 2023 EPPA
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 5, 2023 NPUB
PUBLISHED FOR OPPOSITION
Sep 5, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 16, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 29, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 28, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 27, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 27, 2023 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
May 18, 2023 GPRN
PRIORITY ACTION E-MAILED
May 18, 2023 GPRA
PRIORITY ACTION WRITTEN
May 18, 2023 CPRA
NOTIFICATION OF PRIORITY ACTION E-MAILED
May 17, 2023 GPRN
PRIORITY ACTION E-MAILED
May 17, 2023 GPRA
PRIORITY ACTION WRITTEN
May 17, 2023 CPRA
ASSIGNED TO EXAMINER
May 5, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 10, 2022 NWOS
NEW APPLICATION ENTERED
Jul 23, 2022 NWAP